US House Democrat proposes ban on pharma ‘pay-for-delay’ deals
A bill introduced in the US House on Thursday would prohibit, with some exceptions, branded drug manufacturers from compensating generic and biosimilar drugmakers to delay market entry through patent settlements, a...To view the full article, register now.
Already a subscriber? Click here to view full article